Ignite Creation Date:
2025-12-24 @ 3:45 PM
Ignite Modification Date:
2025-12-26 @ 10:40 AM
Study NCT ID:
NCT05197192
Status:
RECRUITING
Last Update Posted:
2025-08-17
First Post:
2021-09-27
Is NOT Gene Therapy:
True
Has Adverse Events:
False
Brief Title:
A Phase-3-trial of Acalabrutinib, Obinutuzumab & Venetoclax Compared to Obinutuzumab and Venetoclax in Previously Untreated Patients With High Risk CLL
Sponsor:
German CLL Study Group
Organization:
Key Dates - Follows AllAPIJSON File Order
Start Date:
2022-04-19
Start Date Type:
ACTUAL
Primary Completion Date:
2028-05
Primary Completion Date Type:
ESTIMATED
Completion Date:
2028-05
Completion Date Type:
ESTIMATED
First Submit Date:
2021-09-27
First Submit QC Date:
None
Study First Post Date:
2022-01-19
Study First Post Date Type:
ACTUAL
Results First Submit Date:
None
Results First Submit QC Date:
None
Results First Post Date:
None
Results First Post Date Type:
None
Results First Post QC Date:
None
Results First Post QC Date Type:
None
Disp First Submit Date:
None
Disp First Submit QC Date:
None
Disp First Post Date:
None
Disp First Post Date Type:
None
Last Update Submit Date:
2025-08-13
Last Update Post Date:
2025-08-17
Last Update Post Date Type:
ACTUAL